ClinicalTrials.gg
CompletedNCT00457418Updated Jun 7, 2017Results posted

High-Dose PEG-Intron Pharmacokinetic Study in Patients With Melanoma (Study P04831 AM2)

A Phase 1 interventional study of PEG-Intron in Melanoma, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-06-07.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing peginterferon alfa-2b in Melanoma — none open to participants now, none under way, none of them phase 3. peginterferon alfa-2b · Melanoma.

Enrollment
9th of 14
32 · median 36
Started
2007
the only one that year
Phase 1
5 of 14
none open now
Registered
4th of 14
by date
Lead sponsor
5 of 14
Merck Sharp & Dohme LLC

Among the 14 studies testing peginterferon alfa-2b in Melanoma, this one is the 9th largest by enrollment, is the only one that started in 2007, is one of 5 in phase 1, and was the 4th registered.

Melanoma

3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.

Browse Melanoma studies →

Open to participants now

None of the 14 studies testing peginterferon alfa-2b in Melanoma is open now. The open studies under Melanoma, anywhere →

About peginterferon alfa-2b

peginterferon alfa-2b: first FDA approval 2001 (PEGINTRON), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 467 Melanoma studies recruiting now, 380 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies testing peginterferon alfa-2b in Melanoma as a file.
02

Study summary

The purpose of this study is to establish the pharmacokinetics of PEG-Intron, administered at a dose of 6 μg/kg/week for 8 weeks (induction treatment), followed by a dose of 3 μg/kg/week for up to 252 weeks (maintenance treatment), in patients with high risk melanoma.

03

Conditions studied

  • Melanoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects at least 18 years of age, of either sex, and of any race.
  • or histologically-confirmed melanoma, arising from a cutaneous or unknown site of origin, at Stages IIB, IIC, IIIA, IIIB, IIIC according to the American Joint Committee on Cancer (AJCC) 2001 guidelines.
  • Adequate hepatic, renal and bone marrow function within 4 weeks prior to initiation of study treatment.
  • Subjects presenting with synchronous primary and regional melanoma must have had adequate surgical margins surrounding the primary lesion.
  • Full lymphadenectomy must be performed within 90 days prior to initiation of study treatment.
  • (ECOG) performance status of 0 or 1.
  • Give according to International Conference on Harmonisation - Good Clinical Practice (ICH-GCP) and national/local policy.
  • Be able to adhere to dose and visit schedules.
  • Female subjects of must be using a medically accepted method of prior to Screening and agree to continue its use during the study or be surgically sterilized.
  • Female subjects of childbearing potential must have a negative serum pregnancy test at Screening.

Exclusion criteria

Exclusion Criteria:

  • Female subjects who are pregnant, intend to become pregnant, or are breastfeeding.
  • Previous treatment with interferon alpha, chemotherapy or immunotherapy for melanoma.
  • Ocular melanoma, or melanoma of the mucous membranes.
  • Evidence of distant or non-regional lymph node .
  • In-transit melanoma, even if the lesion has been resected.
  • Disease that cannot be completely surgically resected.
  • Lack of recovery from recent surgery.
  • Prior within the past 5 years, except surgically cured squamous cell carcinoma of the skin, successfully resected early stage cutaneous melanoma, or cervical carcinoma in situ.
  • Severe cardiovascular disease.
  • Thyroid dysfunction not responsive to therapy.
  • Uncontrolled diabetes mellitus (in the opinion of the investigator).
  • Active disease.
  • Active and/or uncontrolled infection.
  • History of seropositivity for (HIV).
  • Pre-existing psychiatric condition.
  • Clinical diagnosis of substance abuse of one or more of the following drugs within the following timeframes (excluding time spent in detoxification, hospitalization or incarceration):

    • Alcohol, intravenous drug use, inhalational, psychotropics, narcotics, cocaine, prescription or over-the-counter drugs: within 1 year of the Screening visit.
    • Methadone, buprenorphine hydrochloride (HCl), and/or butorphanol tartrate: within 1 year of Screening visit, unless subject has drug screen negative for other (non-narcotic) drugs documented in the past year and repeated negative within 2 months of Screening visit.
    • Multi-drug abuse (2 or more substances in 16a and 16b): within 3 years of Screening visit.
    • Marijuana:

      • If historic use is deemed excessive by the principal investigator (or medically qualified individual), or is interfering with the subject's life, then the subject is not eligible and should not be screened.
      • If marijuana use is not deemed excessive by principal investigator and does not interfere with life, subject must discontinue any current use of marijuana prior to entry into study.
  • Medical condition requiring chronic systemic .
  • Known allergy to the drug substance or any of the in the PEG-Intron formulation.
  • Any situation or condition that, in the opinion of the investigator, may interfere with optimal participation in the study.
  • Use of any drugs within 30 days of study entry.
  • Participation in other clinical studies of investigational treatments.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    PEG-Intron

    6 ug/kg/week, SC (first 8 weeks) 3 ug/kg/week, SC (252 weeks \[weeks 9-260\], maintenance)

    Drug: PEG-Intron

Interventions

  • Also known as: SCH 054031, peginterferon alfa-2b

06

What researchers measure

Primary outcomes

  1. Area Under the Curve (AUC) of PEG-Intron at 12 Weeks

    AUC was defined as the actual body exposure to drug after administration of a dose of the drug.

    Time frame: Predose, and 24, 48, 72, 96, and 168 hours postdose at 12 weeks

  2. Maximum Serum Concentration (Cmax) of PEG-Intron at 12 Weeks

    Cmax was defined as observed maximum plasma concentration.

    Time frame: Predose, and 24, 48, 72, 96, and 168 hours postdose at 12 weeks

  3. Average Concentration Within the Dosing Interval (Cavg) of PEG-Intron at 12 Weeks

    Cavg was defined as average plasma concentration.

    Time frame: Predose, and 24, 48, 72, 96, and 168 hours postdose at 12 weeks

  4. Minimum Serum Concentration (Cmin) of PEG-Intron at 12 Weeks

    Cmin was defined as observed minimum plasma concentration.

    Time frame: Predose, and 24, 48, 72, 96, and 168 hours postdose at 12 weeks

  5. Observed Time to Achieve Cmax (Tmax) of PEG-Intron at 12 Weeks

    Tmax was defined as time of maximum plasma concentration.

    Time frame: Predose, and 24, 48, 72, 96, and 168 hours postdose at 12 weeks

  6. Apparent Clearance(CL/F) of PEG-Intron at 12 Weeks

    CL/F was defined apparent clearance - the volume of plasma in the vascular compartment cleared of drug per unit of time and per kilogram of body weight by the processes of metabolism and excretion.

    Time frame: Predose, and 24, 48, 72, 96, and 168 hours postdose at 12 weeks

Secondary outcomes

  1. Number of Participants Who Experienced an Adverse Event (AE)

    An adverse event (AE) was defined as any untoward medical occurrence or unfavorable and unintended sign in a subject administered a pharmaceutical product, biologic (at any dose), or medical device, whether or not considered related to the use of that product.

    Time frame: Entire study duration (up to 5 years)

07

Results

Posted Jul 31, 2013

Participant flow

Pharmacokinetic (PK) Sampling Phase
Participant flow — Pharmacokinetic (PK) Sampling Phase
MilestonePEG-Intron
Started32
Completed27
Not completed5
Withdrew: Adverse event2
Withdrew: Progression of disease1
Withdrew: Non-compliance with protocol2
Post PK Maintenance
Participant flow — Post PK Maintenance
MilestonePEG-Intron
Started31
Completed3
Not completed28
Withdrew: Adverse event10
Withdrew: Progression of disease6
Withdrew: Withdrawal by subject11
Withdrew: Lost to follow-up1

Outcome measures

PrimaryArea Under the Curve (AUC) of PEG-Intron at 12 Weeks

AUC was defined as the actual body exposure to drug after administration of a dose of the drug.

Time frame:
Predose, and 24, 48, 72, 96, and 168 hours postdose at 12 weeks
Reported as:
Mean · pg*hr/mL
Area Under the Curve (AUC) of PEG-Intron at 12 Weeks
pg*hr/mLPEG-Intron
Area Under the Curve (AUC) of PEG-Intron at 12 Weeks235000 ± 56400
PrimaryMaximum Serum Concentration (Cmax) of PEG-Intron at 12 Weeks

Cmax was defined as observed maximum plasma concentration.

Time frame:
Predose, and 24, 48, 72, 96, and 168 hours postdose at 12 weeks
Reported as:
Mean · pg/mL
Maximum Serum Concentration (Cmax) of PEG-Intron at 12 Weeks
pg/mLPEG-Intron
Maximum Serum Concentration (Cmax) of PEG-Intron at 12 Weeks2620 ± 865
PrimaryAverage Concentration Within the Dosing Interval (Cavg) of PEG-Intron at 12 Weeks

Cavg was defined as average plasma concentration.

Time frame:
Predose, and 24, 48, 72, 96, and 168 hours postdose at 12 weeks
Reported as:
Mean · pg/mL
Average Concentration Within the Dosing Interval (Cavg) of PEG-Intron at 12 Weeks
pg/mLPEG-Intron
Average Concentration Within the Dosing Interval (Cavg) of PEG-Intron at 12 Weeks1400 ± 336
PrimaryMinimum Serum Concentration (Cmin) of PEG-Intron at 12 Weeks

Cmin was defined as observed minimum plasma concentration.

Time frame:
Predose, and 24, 48, 72, 96, and 168 hours postdose at 12 weeks
Reported as:
Mean · pg/mL
Minimum Serum Concentration (Cmin) of PEG-Intron at 12 Weeks
pg/mLPEG-Intron
Minimum Serum Concentration (Cmin) of PEG-Intron at 12 Weeks626 ± 269
PrimaryObserved Time to Achieve Cmax (Tmax) of PEG-Intron at 12 Weeks

Tmax was defined as time of maximum plasma concentration.

Time frame:
Predose, and 24, 48, 72, 96, and 168 hours postdose at 12 weeks
Reported as:
Median · hours
Observed Time to Achieve Cmax (Tmax) of PEG-Intron at 12 Weeks
hoursPEG-Intron
Observed Time to Achieve Cmax (Tmax) of PEG-Intron at 12 Weeks24.00 (24.00 to 48.00)
PrimaryApparent Clearance(CL/F) of PEG-Intron at 12 Weeks

CL/F was defined apparent clearance - the volume of plasma in the vascular compartment cleared of drug per unit of time and per kilogram of body weight by the processes of metabolism and excretion.

Time frame:
Predose, and 24, 48, 72, 96, and 168 hours postdose at 12 weeks
Reported as:
Mean · L/hr/kg
Apparent Clearance(CL/F) of PEG-Intron at 12 Weeks
L/hr/kgPEG-Intron
Apparent Clearance(CL/F) of PEG-Intron at 12 Weeks0.0129 ± 0.00284
SecondaryNumber of Participants Who Experienced an Adverse Event (AE)

An adverse event (AE) was defined as any untoward medical occurrence or unfavorable and unintended sign in a subject administered a pharmaceutical product, biologic (at any dose), or medical device, whether or not considered related to the use of that product.

Time frame:
Entire study duration (up to 5 years)
Reported as:
Number · participants
Number of Participants Who Experienced an Adverse Event (AE)
participantsPEG-Intron
Number of Participants Who Experienced an Adverse Event (AE)32

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PEG-Intron—9/32 (28.1%)32/32 (100%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventPEG-Intron
ATRIAL FIBRILLATIONCardiac disorders2/32
CARDIAC ARRESTCardiac disorders1/32
GLAUCOMAEye disorders1/32
CHOLECYSTITISHepatobiliary disorders1/32
DRUG HYPERSENSITIVITYImmune system disorders1/32
APPENDICITIS PERFORATEDInfections and infestations1/32
BRONCHITISInfections and infestations1/32
SEPSISInfections and infestations1/32
LOWER LIMB FRACTUREInjury, poisoning and procedural complications1/32
WRIST FRACTUREInjury, poisoning and procedural complications1/32
Most frequent other events
Showing 10 of 67
Most frequent other events
EventPEG-Intron
FATIGUEGeneral disorders29/32
PYREXIAGeneral disorders27/32
DECREASED APPETITEMetabolism and nutrition disorders27/32
CHILLSGeneral disorders26/32
NAUSEAGastrointestinal disorders23/32
HEADACHENervous system disorders23/32
DIARRHOEAGastrointestinal disorders20/32
MYALGIAMusculoskeletal and connective tissue disorders18/32
INJECTION SITE REACTIONGeneral disorders13/32
HYPERTRIGLYCERIDAEMIAMetabolism and nutrition disorders13/32

Baseline characteristics

Age, Continuous
Age, Continuous(years)PEG-Intron
Mean49.1 ± 12.8
Sex: Female, Male
Sex: Female, Male(Participants)PEG-Intron
Female10
Male22
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Daud AI, Xu C, Hwu WJ, Urbas P, Andrews S, Papadopoulos NE, Floren LC, Yver A, Deconti RC, Sondak VK. Pharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon alpha-2b in patients with resected high-risk melanoma. Cancer Chemother Pharmacol. 2011 Mar;67(3):657-66. doi: 10.1007/s00280-010-1326-9. Epub 2010 May 28. PubMed 20509027 ↗

Individual participant data

Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2007 to primary completion in May 2008, 15 months.

Results were first posted in Jul 2013, 5 years 2 months after primary completion.

Of 225 industry-sponsored phase 1 interventional studies under Melanoma, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 66. This study's 15 months is below that.

Counting every sponsor, half of 411 studies reached it within 49 months; a quarter within 31 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 5, 2007
First posted
Apr 6, 2007
StartActual
Feb 20, 2007
Primary completionActual
May 27, 2008
CompletionActual
Jul 11, 2012
Results first posted
Jul 31, 2013
Last update
Jun 7, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 7, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00457418
Responsible party
Sponsor
First posted
Apr 6, 2007
Start date
Feb 20, 2007
Primary completion
May 27, 2008
Completion
Jul 11, 2012
Results posted
Jul 31, 2013
Last update
Jun 7, 2017
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Peginterferon alfa-2b

Start the discussion